Understand the source comparison
Cagrilintide vs Tirzepatide: Single Compound vs Dual-Receptor Targeting
Tirzepatide (branded as Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist. A single molecule engineered to activate both incretin pathways with a single injection. Cagrilintide, by contrast, activates only amylin receptors and requires combination wi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide (branded as Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist. A single molecule engineered to activate both incretin pathways with a single injection. Cagrilintide, by contrast, activates only amylin receptors and requires combination with a separate GLP-1 compound to achieve comparable multi-pathway effects. The question researchers face: is one injection of a dual-mechanism compound preferable to two separate injections targeting three pathways?
- Tirzepatide's dual agonism produces 15mg dose-dependent weight loss of approximately 20.9% at 72 weeks (SURMOUNT-1 trial data). It works by binding GLP-1 receptors to suppress appetite and slow gastric motility, while simultaneously activating GIP receptors to enhance insulin secretion and promote fat oxidation in adipose tissue. The GIP component is what differentiates tirzepatide from pure GLP-1 agonists. GIP receptor activation increases energy expenditure and shifts substrate utilization toward lipid metabolism rather than glucose.
- Cagrilintide doesn't replicate either of tirzepatide's mechanisms. It doesn't bind GLP-1 or GIP receptors. When paired with semaglutide in the CagriSema protocol, the combination outperforms tirzepatide monotherapy (25.8% vs 20.9% weight loss) because you're layering amylin-mediated brainstem satiety on top of hypothalamic GLP-1 signaling. Two independent hunger circuits rather than one amplified incretin pathway. The trade-off: two injections weekly instead of one.
- The nausea profile differs as well. Tirzepatide's GI side effects stem primarily from its GLP-1 receptor activity (slowed gastric emptying). Cagrilintide's nausea originates from area postrema activation. The same brainstem region that triggers chemotherapy-induced nausea. Clinically, this means cagrilintide nausea responds poorly to standard antiemetics that work on peripheral GI receptors, whereas tirzepatide nausea often resolves with dietary modifications alone. Researchers working with cagrilintide protocols in our experience report higher early-stage dropout rates due to nausea that persists beyond the typical 4–8 week GLP-1 titration window.